"Coherus BioSciences to divest ophthalmology franchise, Cimerli, to Sandoz for $170 million. Deal includes product inventory and access to commercial software
Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI from Coherus BioSciences, Inc. for an upfront cash purchase payment of $170 million.